Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Angle-closure, Primary, Acute

Interventions

DRUG: QPI-1007 Injection
DRUG: (including placebo)

Sponsor

Quark Pharmaceuticals